XNCR News and Press, Xencor Inc. From 10/21/25

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Ph...

2025-10-17 15:00:52 ET More on the markets Bank Profits Accelerate Why I Monitor Junk Bonds And What I See Now Macro Insights: Hot Takes And The Trade War's Resurgence Market crossroads: Oversold stocks outnumber overbought names two-to-one in the S&P 500...

2025-10-17 09:50:31 ET https://markets-headlines.com/wp-content/uploads/2025/10/Natural-Killer-Cell-Therapies-Lead-254B-Immunotherapy-Market-Transformation.mp4 Equity Insider News Commentary Issued on be...

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6 billion by 2033, with institutional investors pouring capital i...

2025-10-14 13:29:54 ET More on Xencor Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts Seeking Alpha’s Quant Rating on Xencor Historical earnings data for...

-- Management to host webcast and conference call on Friday, October 24, 2025 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the upcoming presentation of in...

2025-09-19 17:35:33 ET The last time I wrote about Xencor ( XNCR ), it was with respect to a Seeking Alpha article entitled " Xencor: Plamotamab NHL Data Leads To RA Program Advancement ." With respect to this article, I noted the opportunity that the company had in developi...

2025-09-17 06:08:57 ET ... Read the full article on Seeking Alpha For further details see: Absci Corporation: ABS-101 Has Both First-Gen And Next-Gen Competitors

2025-09-03 15:14:58 ET Shares of infectious disease and oncology concern Vir Biotechnology, Inc. ( VIR ) are down ~65% since enthusiasm generated from initial T cell engager data sparked a rally in January 2025. Its sole remaining infectious disease asset, a combination of tobevibar...

2025-09-03 15:14:48 ET More on Erasca, Xencor, etc. Candel Therapeutics announces $15M in direct offering Incyte granted FDA label expansion for lymphoma therapy Monjuvi Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca ...